Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
How did MoneyWorks4me help subscribers to buy Persistent Systems at Rs. 700/ share in Jan 2020?
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Beryl Drugs Ltd Stock Analysis

Small Cap
Evaluated by 160 users | BSE: 524606 | NSE: |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Capital Employed 0.92%2.97%6.99%5.33%3.22%2.89%2.99%9.18%7.39%2.31%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 7.59.314.614.613.313.11115.11312.816
Y-o-Y Gr. Rt.-22.8%58.1%-0.1%-9.1%-1.4%-16.2%37.8%-14.4%-1.1%-
Adjusted EPS (Rs.) -0.050.170.730.520.150.180.211.321.180.091.53
Y-o-Y Gr. Rt.-NA329.4%-28.8%-71.2%20%16.7%528.6%-10.6%-92.4%-
Book Value per Share (Rs.) 11.1511.3212.112.6212.7613.0913.3513.114.814.9916.26
Adjusted Net Profit 00.10.40.30.10.10.10.70.60.11
Net Op. Cash Flow (Rs. Cr.) 0.20.80.8-0.30.7-0.10.3-0.13.40.2-
Debt to Cash Flow from Ops 5.181.171.13-4.782.47-13.56.34-14.780.9728.33-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Beryl Drugs Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 6.1%-0.7%5.3%-1.1%
Adjusted EPS NA-9.7%-24.6%-92.4%
Book Value per Share 3.33.33.91.3
Share Price -4.3% -8% 11% 92.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Equity (%) -0.451.566.354.181.211.351.589.988.40.639.79
Operating Profit Margin (%) 4.75.116.065.075.33.814.56.878.027.0712.46
Net Profit Margin (%) -0.330.952.571.790.590.680.974.444.60.374.85
Debt to Equity 0.180.160.150.240.270.250.250.220.430.69-
Working Capital Days 214176109124165170215185195186-
Cash Conversion Cycle 119823849801041491149572-
Loading price chart...
Entity Percentage Holding
Promoters 24.92%
Non-Institutions 75.08%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Beryl Drugs Ltd's earnings have declined by -9.7%, whereas share price has declined -8% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Beryl Drugs Ltd share price has declined -4.3% annually (CAGR) over the past ten years.

Data is not available for this company.

Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.

Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. 

The manufacturing facilities of the company are in compliance with WHO GMP specifications.

Company owns brands like

Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.

Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. 

The manufacturing facilities of the company are in compliance with WHO GMP specifications.

Company owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The shares of Beryl Drugs are listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

Products manufactured by the company:

  • Small volume injectables in liquid form
  • Small volume injectables in dry powder form
  • Variety of eye and ear drops
  • I.V.Fluids in polypack and glass bottles
  • Variety of vetrinary medicines

Award/recognition

The company has received ISO 9001:2000 certification for its quality management.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback